Mechanistic and functional characterization of NETs/IL-17 as a therapeutic target in EMT and brain metastasis of lung adenocarcinoma - Report - MDSpire

Mechanistic and functional characterization of NETs/IL-17 as a therapeutic target in EMT and brain metastasis of lung adenocarcinoma

  • By

  • Yong Cai

  • Bin Su

  • Jiying Wang

  • May 25, 2026

  • 0 min

Share

Clinical Report: Exploring the Role of IL-17A in Lung Adenocarcinoma Metastasis

Overview

Revise to clarify the mechanisms linking IL-17A to NET formation and its implications for metastasis.

Background

Lung adenocarcinoma (LUAD) is a leading cause of cancer-related deaths and is particularly known for its tendency to metastasize to the brain. Over 30% of LUAD patients develop brain metastases, which significantly worsen prognosis. Understanding the molecular mechanisms behind this metastasis is crucial for developing effective treatment strategies.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

Rephrase to emphasize the mechanisms and their clinical relevance as highlighted in the source.

Clinical Implications

Detail potential clinical applications of IL-17A inhibitors and NET-targeting therapies.

Conclusion

Make the therapeutic targets more explicit and aligned with the source's conclusions.

Related Resources & Content

  1. The ASCO Post, 2014 -- IL-17A Promotes and GM-CSF Suppresses Circulating Tumor Cells and Metastasis in Colorectal Cancer
  2. The ASCO Post, 2013 -- Epithelial-to-mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–mediated Lysis
  3. Archives of Toxicology, 2021 -- Overcoming Drug Resistance in Cancer through EMT: Innovative Treatment Approaches
  4. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases
  5. The ASCO Post — Role of Epithelial-to-Mesenchymal Transition in Ovarian Cancer
  6. Neutrophil Extracellular Trap Reprograms Cancer Metabolism to Form a Metastatic Niche Promoting Non-Small Cell Lung Cancer Brain Metastasis
  7. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases
  8. ASCO 2024: CROWN: Lorlatinib in der Erstlinie beim metastasierten ALK+ NSCLC – 5-Jahres-Update | congress-x-press

Original Source(s)

Mechanistic and functional characterization of NETs/IL-17 as a therapeutic target in EMT and brain metastasis of lung adenocarcinoma

  • by Yong Cai, Bin Su, Jiying Wang

  • May 25, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant